Aptar Pharma is playing a key role in the next phase of COVID-19 vaccine development, providing specialized nasal delivery systems for CastleVax’s Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate. This collaboration represents a significant step forward in exploring mucosal immunity as a potential pathway to more effective and broadly protective vaccines against respiratory viruses. The trial, which began in January 2026, aims to assess whether delivering the vaccine directly to the nasal passages can elicit a stronger immune response at the site of infection than traditional intramuscular injections.
The current standard for COVID-19 vaccination involves injecting the vaccine into the muscle, prompting the body to create antibodies that circulate in the bloodstream. While effective, this approach doesn’t always generate a robust immune response in the mucous membranes lining the respiratory tract – the first line of defense against the virus. Intranasal vaccines, like CVAX-01, are designed to stimulate immune cells directly within the nasal passages, potentially offering enhanced protection against infection and transmission. This approach to intranasal vaccine delivery is gaining traction as researchers seek to improve vaccine efficacy and durability.
Precision Nasal Delivery: Aptar’s Technology
To ensure accurate and effective administration of CVAX-01, CastleVax is utilizing two key technologies from Aptar Pharma: LuerVax™ and Spray Divider™. LuerVax™ is a specialized adapter that connects a standard syringe to a nasal spray nozzle, allowing for precise dosing. The Spray Divider™ technology further refines the process by enabling accurate bilateral dosing, ensuring that each nostril receives an equal amount of the vaccine. According to AptarGroup, Inc., these solutions support their commitment to advancing drug delivery and next-generation vaccine development, backed by comprehensive regulatory and technical expertise.
The Phase II study will involve approximately 200 U.S. Adults, including individuals considered high-risk and those over the age of 65. Participants will be monitored for six months to evaluate the safety, tolerability, and immune response generated by the intranasal vaccine compared to an FDA-approved injectable mRNA vaccine. Researchers will be looking specifically at whether nasal delivery can provide strong mucosal immunity, a key factor in preventing infection and transmission.
A Shift Towards Needle-Free Vaccination
This collaboration between Aptar Pharma and CastleVax underscores a growing trend within the pharmaceutical industry towards needle-free drug delivery systems. The benefits of such systems extend beyond patient comfort; they can also improve adherence, reduce the risk of accidental needlesticks, and potentially enhance the effectiveness of certain medications. Aptar’s “Pharma Services” platform is designed to facilitate pharmaceutical companies navigate the complexities of developing and manufacturing these advanced delivery systems, from initial design and formulation compatibility to clinical trial support and regulatory guidance.
“We are pleased to support CastleVax in this pivotal trial,” said Alex Theodorakis, President, Aptar Pharma Prescription, in a press statement. “Our goal is to help our partners accelerate the delivery of life-changing therapies by providing reliable, high-performance nasal solutions.”
The Future of Intranasal Medicine
The success of trials like the CastleVax Phase II study is expected to further drive momentum in the respiratory and systemic drug delivery space. The field is rapidly evolving, with researchers exploring new materials, designs, and manufacturing techniques to optimize nasal delivery systems. For professionals interested in learning more about these advancements, the Nasal Formulation and Delivery Summit will be a key event. Aptar Pharma is a key sponsor of the summit, and will join other industry leaders to discuss the future of intranasal medicine.
The summit offers a unique opportunity to explore the science behind these clinical breakthroughs and network with the experts who are shaping the next generation of intranasal medicine. Topics covered will include the latest advancements in mucosal vaccination, the technical evolution of nasal delivery platforms, and the regulatory landscape for these innovative therapies.
As the world continues to grapple with the ongoing threat of respiratory viruses, the development of effective intranasal vaccines represents a promising avenue for improving public health. The ongoing Phase II trial of CVAX-01, powered by Aptar Pharma’s innovative delivery systems, is a significant step towards realizing that potential.
Researchers will continue to monitor the results of the Phase II trial, with data expected to be available later in 2026. Further clinical trials will be necessary to confirm the efficacy and safety of CVAX-01 before it can be considered for regulatory approval. The ongoing research and development efforts in this field hold the promise of a new generation of vaccines that can provide more robust and long-lasting protection against respiratory infections.
Please share your thoughts on this developing story in the comments below.
